Product description
Specifications used to short-term treatment for post-operative pain, moderate or severe acute postoperative pain, etc.
Parecoxib sodium is first developed by Pharmacia as one kind of specific COX-2 inhibitors which can be administered both intravenously and intramuscularly. Its first launch is in 2002 at the UK. Chemical name of Parecoxib sodium is N- [[4- (5-methyl-3-phenyl-4-isoxazolyl) phenyl] sulfonyl] propanamide, sodium salt. It is water-soluble precursor of valdecoxib. It is one kind of celecoxib analgesics of anti-arthritis drugs, used to short-term treatment for post-operative pain, moderate or severe acute postoperative pain, etc. Compared with opioids, selective COX-2 inhibitors can inhibit peripheral and central COX-2 expression, reduce the synthesis of peripheral and central prostaglandins, inhibit allodynia, increase the pain threshold, dual analgesia effects advantage.The Analgesic efficacy of parecoxib has been demonstrated in several studies of anesthesia, orthopedics, gynecology and general surgery and etc. And combined with its fast lasting analgesic properties and good security for postoperative analgesia offers better choice. It is shown from studies,it effects within Seven minutes after administration parecoxib by intravenouse injection, and keep effect for 12 hours. In terms of security, as compared with non-selective steroidal anti-inflammatory drugs, parecoxib has a good gastrointestinal safety, does not affect platelet aggregation and bleeding time, and does not increase cardiovascular risk in a non-cardiovascular surgery. Parecoxib as categoryII(listed foreign and domestic unlisted), we have independent intellectual property rights for it. The technology of this product is both hand-type synthetic technology and new crystallization technology. We have finished the process of research working, and being conducted Stability research, and will apply for registration to SFAD in 2015.